Global Dravet Syndrome Treatment Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Dravet Syndrome Treatment market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Dravet Syndrome Treatment market."
Dravet syndrome is a rare, severe form of intractable epilepsy. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells.
Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include clobazam (Onfi, Frisium) and valproic acid (Depakote, Depakene). Second line treatments include stiripentol (Diacomit), topiramate (Topamax), and the ketogenic diet.

The global Dravet Syndrome Treatment market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dravet Syndrome Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dravet Syndrome Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Biocodex
    Epygenix Therapeutics
    GW Pharmaceuticals
    OPKO Health
    Zogenix
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    First-generation Drug (FGD)
    Second-generation Drug (SGD)
    Third-generation Drug (TGD)

Segment by Application
    Hospital Pharmacy
    Retail Pharmacy
    E- Commerce
    Others